Astellas Pharma (OTCMKTS:ALPMY) Announces Earnings Results

Astellas Pharma (OTCMKTS:ALPMY) issued its quarterly earnings data on Tuesday. The company reported $0.30 EPS for the quarter, Zacks reports. Astellas Pharma had a net margin of 3.26% and a return on equity of 10.40%.

Astellas Pharma Stock Down 1.7 %

Shares of ALPMY stock traded down $0.17 during mid-day trading on Tuesday, reaching $9.52. 153,258 shares of the company’s stock traded hands, compared to its average volume of 246,783. Astellas Pharma has a 12 month low of $9.05 and a 12 month high of $13.14. The company’s 50-day moving average price is $9.87 and its 200-day moving average price is $10.97. The company has a market cap of $17.22 billion, a P/E ratio of 45.31 and a beta of 0.34. The company has a quick ratio of 0.86, a current ratio of 1.10 and a debt-to-equity ratio of 0.41.

Astellas Pharma Company Profile

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.